Journal of Clinical Oncology
Articles in this Issue
Onsite serial monitoring of high grade serous ovarian cancer (HGSOC) mutations in circulating tumor DNA (ctDNA) via droplet digital PCR.
5603 Background: Comprehensive Genomic Profiling (CGP) of tumor and blood samples is increasingly employed for ovarian can...
Clinical outcomes and resource utilization of sepsis in hospitalized patients with hematologic malignancies: A National Inpatient Sample study.
e18628 Background: Sepsis is a major cause of morbidity and mortality among patients with hematologic malignancies, yet ou...
Prospective evaluation of the psychological impact of multicancer early detection (MCED) blood testing: A smartphone-based patient-reported outcomes study.
10542 Background: Earlier detection may reduce cancer mortality by reducing the number of cancers diagnosed at advanced st...
Extracapsular dissection vs superficial parotidectomy for pleomorphic adenomas of parotid gland: An updated systematic review and meta-analysis.
e18086 Background: The optimal surgical approach for small pleomorphic adenomas of the parotid gland is disputed. Extracap...
A URCC NCORP Research Base nationwide phase II randomized controlled trial (RCT) investigating the effect of exercise on chemotherapy-induced peripheral neurotoxicity (CIPN).
12014 Background: Over 60% of patients with cancer receiving taxane, platinum, or other neurotoxic agents experience CIPN,...
Histopathology-verified comparison of FET PET and contrast-enhanced MRI for tumor visualization in glioblastoma.
2049 Background: In glioblastoma, precise visualization is a prerequisite for optimal resection strategies and accurate ra...
Early versus delayed oral feeding after esophagectomy for esophageal cancer: A systematic review and meta-analysis of randomized controlled trials.
e16027 Background: Postoperative oral intake after esophagectomy has traditionally been delayed due to concerns about anas...
Intratumoral dendritic cell (DC1) therapy prior to neoadjuvant chemotherapy in HER2-positive breast cancer (NATASHA trial).
2594 Background: Enhancing the efficacy of neoadjuvant therapy (NAT) while minimizing treatment-related toxicity remains a...
Sinonasal adverse events of immune checkpoint inhibitors: Pharmacovigilance using FAERS.
11146 Background: Immune checkpoint inhibitors (ICIs) are cancer therapies with diverse toxicities, known as immune-relate...
Results of a phase II trial of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-deficient cancers.
10029 Background: Several aggressive pediatric and young adult cancers are characterized by loss of INI1 expression, inclu...
Enhancing resident learning in anticoagulation management: A single-institution quality improvement study with comparison to large language models.
e23308 Background: Anticoagulation management is complicated by evolving guidelines and patient-specific factors, particul...
Developing a pan-cancer foundation model for digital patient representation and clinical prediction across real-world oncology data.
e23012 Background: Foundation models in oncology (FM onc ) enable creation of unif...
Phase 2 trial of TIL therapy for metastatic uveal melanoma: Evaluation of T cell potency and an in situ precision biomarker.
2512 Background: Uveal melanoma (UM) is a rare eye cancer that frequently metastasizes to the liver and responds poorly to...
First-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic <i>KRAS</i> G12C+ non–small cell lung cancer (NSCLC): Results from the Krascendo-170 study.
8510 Background: Krascendo 170 (NCT05789082) is an open-label, phase Ib/II, dose-finding and -expansion study of divarasib...
Translating meta-analytic risk into absolute survival: Projection modeling of secondary-type mutations in ELN-favorable NPM1-mutated acute myeloid leukemia.
e18536 Background: Nucleophosmin 1 (NPM1) mutation is traditionally associated with a favorable prognosis in acute myeloid...
Exploring diversity and composition of sulfidogenic gut bacteria in breast cancer.
574 Background: Sulfidogenic bacteria produce hydrogen sulfide, the excess of which is genotoxic and proinflammatory and i...
Efficacy and safety of QL1706-based combination therapy in recurrent or metastatic endometrial carcinoma previously treated with chemotherapy and immune checkpoint inhibitors: A single-arm, prospective, phase II trial.
TPS2694 Background: Patients with advanced endometrial cancer who have progressed after platinum-based chemotherapy and im...
Real-world patterns of hyperlipidemia and cardiometabolic toxicity in patients with ALK-fusion– positive NSCLC treated with lorlatinib.
e20724 Background: Lorlatinib is highly effective for ALK-rearranged NSCLC but is associated with hyperlipidemia (HLD) and...
Reducing oncology transportation burden with decentralized treatment trials.
e23003 Background: Poor accrual to oncology treatment trials due to numerous factors, including patient burden, has been w...
Targeting stromal FAK signaling to address chemotherapy and immunotherapy resistance in gastric-type endocervical adenocarcinoma.
5524 Background: Gastric-type endocervical adenocarcinoma (GAC) is a rare, HPV-independent cervical cancer subtype with pr...
Identification of tumor repopulating–like epithelial cells and a repair-dominant niche in pathological responders after neoadjuvant chemo-immunotherapy for HNSCC.
6070 Background: Neoadjuvant PD-1 blockade plus chemotherapy can induce deep pathologic responses in HNSCC. However, pCR i...
Clinical trial in progress: Phase II trial of neoadjuvant tebentafusp in patients with locally advanced primary uveal melanoma.
TPS9607 Background: Uveal melanoma (UM) is the most common intraocular malignant tumor in adults. Primary UM are effective...
Longitudinal trends in pembrolizumab uptake for triple-negative breast cancer (TNBC): A comparative analysis of Appalachian and non-Appalachian populations at a tertiary care center.
e23412 Background: Appalachian populations face unique barriers leading to cancer care disparities. As pembrolizumab becom...
HRD-positive breast cancer genomics: Cross-application of ovarian cancer HRD scores.
1037 Background: Homologous recombination deficiency (HRD) is a well-established biomarker for PARP inhibitor (PARPi) ther...
Surgical outcomes and postoperative complications of robotic versus conventional nipple-sparing mastectomy in breast cancer: A meta-analysis.
585 Background: Breast cancer is the most common type of cancer, affecting millions of women worldwide. Nipple-sparing mas...